跳至主要内容
临床试验/NCT01180764
NCT01180764撤回4 期

Effects of Lovaza Monotherapy vs. Placebo on Composition and Function of HDL and Other Lipoproteins, and on Other Lipid-Related Parameters

University of Utah1 个研究点 分布在 1 个国家开始时间: 2010年8月最近更新:
适应症
干预措施

试验速览

阶段
4 期
状态
撤回
试验地点
1
主要终点
HDL Composition

研究概览

简要总结

Study hypothesis: Lovaza (purified prescription fish oil) is likely to help HDL (the "good cholesterol") work better.

Study summary: We are testing effects of Lovaza versus placebo, on various aspects of HDL and other lipoproteins, in patients with high triglyceride levels.

Study funding: This study is being funded by an investigator-initiated research grant from Glaxo Smith Kline.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)

入排标准

年龄范围
35 Years 至 75 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • 未提供

排除标准

  • 未提供

研究组 & 干预措施

Lovaza

Experimental

Lovaza 4g po qd

干预措施: Lovaza (Omega-3 acid ethyl esters) (Drug)

Placebo

Placebo Comparator

Matching placebo

干预措施: Placebo (Drug)

结局指标

主要结局

HDL Composition

时间窗: 12 weeks

HDL composition (protein and lipid) by size (gel filtration column)

次要结局

  • HDL cholesterol composition by density subfraction(12 weeks)
  • Safety(12 weeks)

研究者

申办方类型
Other

研究点 (1)

Loading locations...

相似试验